Kirk P Conrad

US Patent:

7878978, Feb 1, 2011

Filed:

Mar 18, 2005

Appl. No.:

11/084670

Inventors:

Kirk P. Conrad - Cranberry Township PA, US
Sanjeev G. Shroff - Pittsburgh PA, US

Assignee:

University of Pittsburgh- Of The Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

A61B 5/00

US Classification:

600485, 600481, 600500

Abstract:

The present invention provides methods for increasing arterial compliance. The methods generally involve administering to an individual in need thereof an effective amount of relaxin. The present invention further provides methods of increasing arterial compliance in individuals who have Type 1 or Type 2 diabetes. The present invention further provides methods of increasing arterial compliance in perimenopausal, menopausal, and post-menopausal women. The present invention further provides methods of increasing arterial compliance in individuals who have or who are at risk of developing age-associated arterial stiffness.

US Patent:

8574851, Nov 5, 2013

Filed:

Nov 24, 2009

Appl. No.:

13/129597

Inventors:

Dennis Stewart - Los Gatos CA, US
Kirk P. Conrad - Gainesville FL, US
Arundhathi Jeyabalan - Pittsburgh PA, US

Assignee:

Corthera, Inc. - San Mateo CA
University of Pittsburgh-Of the Commonwealth System of Higher Education - Pittsburgh PA
University of Florida Research Foundation, Inc. - Gainesville FL

International Classification:

G01N 33/53
A61K 38/22

US Classification:

435 71, 514 127

Abstract:

The present disclosure relates to methods for detecting an increased risk of preeclampsia, determining the presence of preeclampsia, reducing the likelihood that preeclampsia will develop and treating preeclampsia. It also provides methods of measuring relaxin levels in a biological sample of a pregnant woman.

US Patent:

20020019349, Feb 14, 2002

Filed:

Feb 9, 2001

Appl. No.:

09/780752

Inventors:

Kirk Conrad - Cranberry Township PA, US
Martyn Lewis - Menlo park CA, US
Elaine Unemori - Oakland CA, US
Xinfan Huang - Menlo Park CA, US
Carol Tozzi - Jackson NJ, US

International Classification:

A61K038/00

US Classification:

514/012000

Abstract:

The invention relates to methods of treating diseases related to vasodilation, generally comprising administering to an individual an effective amount of a pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females, and is therefore useful in treating a wide variety of diseases relating to vasoconstriction.

US Patent:

20040266685, Dec 30, 2004

Filed:

Apr 5, 2004

Appl. No.:

10/819039

Inventors:

Kirk Conrad - Cranberry Township PA, US
Martyn Lewis - Menlo Park CA, US
Elaine Unemori - Oakland CA, US
Xinfan Huang - Menlo Park CA, US
Carol Tozzi - Jackson NJ, US

International Classification:

A61K038/17

US Classification:

514/012000

Abstract:

The invention relates to methods of treating diseases related to vasodilation, generally comprising administering to an individual an effective amount of a pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females, and is therefore useful in treating a wide variety of diseases relating to vasoconstriction.

US Patent:

20110171650, Jul 14, 2011

Filed:

Sep 16, 2009

Appl. No.:

13/119213

Inventors:

Kirk P. Conrad - Gainesville FL, US
Arundhathi Jeyabalan - Pittsburgh PA, US
Sandra Anne Founds - Wexford PA, US
William Allen Hogge - Pittsburgh PA, US

Assignee:

University of Pittsburgh-Of the Commonwealth System of Higher Education - Pittsburgh PA
University of Florida Research Foundation, Inc. - Gainesville FL

International Classification:

C12Q 1/68
G01N 33/53

US Classification:

435 611, 436501, 435 792

Abstract:

Gene expression patterns contemporaneous with early placental development in the first trimester of preeclamptic versus unaffected pregnancies have been obtained. Observation of differences in these gene expression patterns has allowed the identification of biomarkers that are useful in predicting and monitoring preeclampsia. These biomarkers are also useful in screening potential therapeutics for efficacy in the prevention or treatment of preeclampsia.

US Patent:

20130012441, Jan 10, 2013

Filed:

Feb 16, 2012

Appl. No.:

13/398215

Inventors:

Dennis Stewart - Los Gatos CA, US
Kirk P. Conrad - Gainesville FL, US
Arundhathi Jeyabalan - Pittsburgh PA, US
Marion Dahike - Basel, CH

International Classification:

A61K 38/22
C07K 16/26
A61P 43/00
G01N 33/566

US Classification:

514 127, 435 792, 53038824

Abstract:

The present disclosure relates to methods for assessing increased risk of preeclampsia in a pregnant woman. The methods described herein employ measuring relaxin levels, and optionally measuring C-reactive protein levels in a biological sample of a pregnant woman. The disclosure further encompasses methods of reducing the risk of preeclampsia and treating it, once it has occurred by administering a pharmaceutical formulation of relaxin to a pregnant woman.

US Patent:

20130053318, Feb 28, 2013

Filed:

Mar 10, 2011

Appl. No.:

13/582478

Inventors:

Parry Laura - Coburg, AU
Kirk Conrad - Gainesville FL, US

International Classification:

A61K 38/22
A61P 7/10

US Classification:

514 127

Abstract:

The present disclosure relates to methods of modulating aquaporin channels. Particularly, the disclosure provides methods of modulating aquaporin channels in a tissue of a mammal by administering relaxin.

US Patent:

20140057832, Feb 27, 2014

Filed:

Nov 5, 2013

Appl. No.:

14/071705

Inventors:

Kirk P. Conrad - Gainesville FL, US
Sanjeev G. Shroff - Pittsburg PA, US

Assignee:

University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

A61K 38/22

US Classification:

514 19, 514 127, 514 73, 514 69, 514 74

Abstract:

The present invention provides methods for increasing arterial compliance. The methods generally involve administering to an individual in need thereof an effective amount of relaxin. The present invention further provides methods of increasing arterial compliance in individuals who have Type 1 or Type 2 diabetes. The present invention further provides methods of increasing arterial compliance in perimenopausal, menopausal, and post-menopausal women. The present invention further provides methods of increasing arterial compliance in individuals who have or who are at risk of developing age-associated arterial stiffness.